Deerfield Management Company, L.P. (Series C) Reata Pharmaceuticals Inc Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$100.0 - $143.02 $30 Million - $42.9 Million	-300,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$78.27 - $151.29 $9.39 Million - $18.2 Million	-120,000 Reduced 28.57%	300,000 $42.5 Million
Q1 2021 May 17, 2021	BUY	$94.25 - $132.81 $9.43 Million - $13.3 Million	100,000 Added 31.25%	420,000 $41.9 Million
Q4 2020 Feb 16, 2021	SELL	$102.03 - $184.62 $13.1 Million - $23.6 Million	-128,000 Reduced 28.57%	320,000 $39.6 Million
Q3 2020 Nov 16, 2020	BUY	$93.53 - $163.34 $17.4 Million - $30.4 Million	186,235 Added 71.15%	448,000 $43.6 Million
Q2 2020 Aug 14, 2020	BUY	$126.3 - $176.56 $9.84 Million - $13.8 Million	77,900 Added 42.37%	261,765 $40.8 Million
Q1 2020 May 15, 2020	BUY	$124.16 - $247.74 $10.4 Million - $20.8 Million	83,865 Added 83.87%	183,865 $26.5 Million
Q4 2019 Feb 14, 2020	SELL	$74.57 - $217.92 $7.23 Million - $21.1 Million	-97,000 Reduced 49.24%	100,000 $20.4 Million
Q2 2019 Aug 14, 2019	SELL	$77.72 - $94.35 $13 Million - $15.8 Million	-167,000 Reduced 45.88%	197,000 $18.6 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $76.44 $3.41 Million - $5.35 Million	70,000 Added 23.81%	364,000 $20.4 Million
Q3 2018 Nov 14, 2018	SELL	$35.64 - $92.06 $11.2 Million - $29 Million	-315,554 Reduced 51.77%	294,000 $24 Million
Q2 2018 Aug 14, 2018	BUY	$19.94 - $40.96 $4.38 Million - $8.99 Million	219,554 Added 56.3%	609,554 $21.3 Million
Q4 2017 Feb 14, 2018	BUY	$22.39 - $33.27 $4.48 Million - $6.65 Million	200,000 Added 105.26%	390,000 $11 Million
Q3 2017 Nov 13, 2017	BUY	$26.29 - $31.88 $5 Million - $6.06 Million	190,000	190,000 $5.91 Million

Others Institutions Holding RETA

# of Institutions

Shares Held

62.7K

Call Options Held

Put Options Held

View Full List

About REATA PHARMACEUTICALS INC

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

More about RETA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account